These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 22960850

  • 1. Monoamine oxidase inhibitors and neuroprotection: a review.
    Al-Nuaimi SK, Mackenzie EM, Baker GB.
    Am J Ther; 2012 Nov; 19(6):436-48. PubMed ID: 22960850
    [Abstract] [Full Text] [Related]

  • 2. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
    Baker GB, Sowa B, Todd KG.
    J Psychiatry Neurosci; 2007 Sep; 32(5):313-5. PubMed ID: 17823646
    [No Abstract] [Full Text] [Related]

  • 3. Monoamine oxidase inhibitors, their structural analogues, and neuroprotection.
    Sowa BN, Holt A, Todd KG, Baker GB.
    Indian J Exp Biol; 2004 Sep; 42(9):851-7. PubMed ID: 15462176
    [Abstract] [Full Text] [Related]

  • 4. An update on amine oxidase inhibitors: multifaceted drugs.
    Song MS, Matveychuk D, MacKenzie EM, Duchcherer M, Mousseau DD, Baker GB.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul 01; 44():118-24. PubMed ID: 23410524
    [Abstract] [Full Text] [Related]

  • 5. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M, Maruyama W.
    Expert Rev Neurother; 2009 Aug 01; 9(8):1233-50. PubMed ID: 19673610
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 01; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 7. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP, Gleiter CH, Möller HJ.
    Nervenarzt; 1996 May 01; 67(5):339-47. PubMed ID: 9005342
    [Abstract] [Full Text] [Related]

  • 8. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
    Berry MD, Juorio AV, Paterson IA.
    Prog Neurobiol; 1994 Oct 01; 44(2):141-61. PubMed ID: 7831475
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan 01; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 10. [Antidepressive drugs and their clinical use].
    Meoni GC.
    Clin Ter; 1972 Jun 30; 61(6):545-72. PubMed ID: 4592993
    [No Abstract] [Full Text] [Related]

  • 11. A neglected modality in psychiatric treatment--the monoamine oxidase inhibitors.
    Johnson WC.
    Dis Nerv Syst; 1975 Sep 30; 36(9):521-5. PubMed ID: 1175468
    [Abstract] [Full Text] [Related]

  • 12. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR, Burrows GD.
    J Neural Transm Suppl; 1989 Sep 30; 28():53-63. PubMed ID: 2677243
    [Abstract] [Full Text] [Related]

  • 13. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb 30; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 14. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR.
    Am J Geriatr Pharmacother; 2006 Dec 30; 4(4):330-46. PubMed ID: 17296539
    [Abstract] [Full Text] [Related]

  • 15. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G, Finberg JP, Youdim MB.
    Clin Neuropharmacol; 1993 Dec 30; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [Abstract] [Full Text] [Related]

  • 16. [A behavioral and neurochemical study on the mechanism of the anxiolytic effect of monoamine oxidase inhibitors].
    Maki Y.
    Hokkaido Igaku Zasshi; 2001 May 30; 76(3):133-42. PubMed ID: 11481866
    [Abstract] [Full Text] [Related]

  • 17. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.
    Matveychuk D, MacKenzie EM, Kumpula D, Song MS, Holt A, Kar S, Todd KG, Wood PL, Baker GB.
    Cell Mol Neurobiol; 2022 Jan 30; 42(1):225-242. PubMed ID: 33839994
    [Abstract] [Full Text] [Related]

  • 18. Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders.
    Dhiman P, Malik N, Sobarzo-Sánchez E, Uriarte E, Khatkar A.
    Molecules; 2019 Jan 24; 24(3):. PubMed ID: 30678358
    [Abstract] [Full Text] [Related]

  • 19. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I.
    Neuropsychopharmacol Hung; 2008 Mar 24; 10(1):15-22. PubMed ID: 18771016
    [Abstract] [Full Text] [Related]

  • 20. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O, Amit T, Bar-Am O, Youdim MB.
    Prog Neurobiol; 2010 Nov 24; 92(3):330-44. PubMed ID: 20600573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.